Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Antistax® | Experimental | 1 tablet per day for 12 weeks |
|
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antistax® | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in limb volume determination | water displacement method | Baseline, day 84 |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in limb volume determination | water displacement method | Baseline, day 21 and day 42 |
| Changes in the calf circumference | in centimeters |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Concomitant diseases:
Previous treatments:
Concomitant treatment/non-drug therapy exclusion criteria:
Other exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33141449 | Derived | Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014689 | Venous Insufficiency |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C522873 | Antistax |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline, at day 21, 42 and 84 |
| Changes in the ankle circumference | in centimeters | Baseline, at day 21, 42, and 84 |
| Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS) | Baseline, at day 21, 42, and 84 |
| Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS) | day 84 |
| Global assessment of efficacy by the investigator on a 4-point VRS | day 84 |
| Global assessment of tolerability by the patient on a 4-point VRS | day 84 |
| Global assessment of tolerability by the investigator on a 4-point VRS | Day 84 |
| Number of patients with adverse events | up to 12 weeks |
| Number of patients with clinically significant changes in laboratory values | Baseline, week 12 |
| Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR)) | Baseline, up to 12 weeks |